HLA-DR: Key Immune System Protein (P11442)

Target Name: HLA class II histocompatibility antigen DR (HLA-DR)

NCBI ID: P11442

HLA class II histocompatibility antigen DR (HLA-DR)

Other Name(s): HLA-DR

HLA-DR: Key Immune System Protein

HLA class II histocompatibility antigen DR (HLA-DR) is a human leukocyte antigen (HLA) that is expressed on the major histocompatibility complex (MHC) class II molecules. MHC class II molecules are a type of immune system protein that play a crucial role in presenting antigens to the T-cells, which are responsible for cell-mediated immunity. HLA-DR is one of the many antigens that are expressed on the MHC class II molecules.

HLA-DR is a glycoprotein that consists of two heavy chains and two light chains. The heavy chains contain four constant (C) regions and one variable (V) region, while the light chains contain one variable (V) region and one constant (C) region. HLA-DR is typically expressed in the dendritic region of the MHC class II molecules, which is the region that is involved in presenting antigens to T-cells.

HLA-DR is a key molecule in the immune system because it helps to determine the self-reactive status of T-cells. T-cells are a type of immune cell that are responsible for cell-mediated immunity, and they have the ability to recognize and respond to antigens that are specific for their MHC class II molecules. HLA-DR is the antigen that is recognized by T-cells when they are exposed to an antigen that is specific for their MHC class II molecules.

HLA-DR is also a potential drug target in cancer. Cancer cells can often evade the immune system's defenses by expressing MHC class II molecules that are not recognized by T-cells. HLA-DR is one of the antigens that can help to identify cancer cells that have this characteristic. By targeting HLA-DR with drugs, researchers may be able to enhance the immune system's ability to recognize and destroy cancer cells.

HLA-DR is also a potential biomarker for cancer. The expression of HLA-DR on cancer cells can be used as a diagnostic marker for the disease. For example, researchers have used HLA-DR to diagnose several types of cancer, including lung cancer, breast cancer, and melanoma. In addition, HLA-DR has also been used as a biomarker to monitor the effectiveness of cancer treatments. For example, researchers have used HLA-DR to assess the response of cancer cells to different treatments, including chemotherapy and radiation therapy.

In conclusion, HLA-DR is a key molecule in the immune system that is involved in presenting antigens to T-cells. It is also a potential drug target and biomarker for cancer. Researchers are currently working to develop new treatments for cancer by targeting HLA-DR with drugs. By the end of the year, it is likely that we will have several new treatments available for cancer that target HLA-DR.

Protein Name: HLA Class II Histocompatibility Antigen DR (HLA-DR)

The "HLA class II histocompatibility antigen DR (HLA-DR) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA class II histocompatibility antigen DR (HLA-DR) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets